HIGH POINT,TransTech Pharma has completed Phase I of clinical trials for its first drug, which is a proposed treatment for blood clotting disorders.
The drug candidate is known as TTP889. TransTech bills it as an alternative to the one orally administered anticoagulant on the market and sees the blood clot treatment market as reaching $15 billion a year over the next decade. TransTech cited projections from Data Monitor.
“The drug was safe at all doses, single and multiple, tested in both young and elderly healthy subjects at blood levels well above the therapeutic range with no test-article related adverse events observed,” the company said.
Phase II trials will begin in September.